Special Issue

State-of-the-Art Drug Discovery in the USA

Message from the Guest Editor

Modes of drug discovery shift over time; the new path engages digital technologies, AI drug design, modeling-based safety, and efficacy determination. The class of new drugs now comprises biological proteins, gene and cell therapy, and gene editing. mRNA vaccines and protein translation is changing the scope, returning the delivery to body cells instead of pills and injections. The AlphaFold capability to predict most complex structures, including proteins and receptors, will facilitate the creation of new drugs that had no treatment, such as the autoimmune disorders. Therefore, we invite all authors actively contributing to drug discovery and development in the USA to participate in this Special Issue. Original research articles and reviews dealing with new strategies with the potential to provide novel treatments in the short term will be welcomed, as will manuscripts dealing with the hottest topics in drug discovery and cutting-edge methodological advances, including emerging industry trends and strategies in relationship with recent drug approvals.

Guest Editor

Prof. Dr. Sarfaraz K. Niazi

College of Pharmacy, University of Illinois, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (31 December 2023)

Biomedicines

MDPI

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).